- Home
- TNGX vs MKTX Comparison
TNGX vs MKTX Comparison
Compare TNGX & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TNGX | MKTX |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.6B |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | TNGX | MKTX |
|---|---|---|
| Price | $22.54 | $163.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $21.78 | ★ $204.88 |
| AVG Volume (30 Days) | ★ 2.0M | 991.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | ★ 26.89 | N/A |
| EPS | N/A | ★ 4.13 |
| Revenue | $62,384,000.00 | ★ $397,471,000.00 |
| Revenue This Year | N/A | $10.14 |
| Revenue Next Year | N/A | $7.22 |
| P/E Ratio | ★ N/A | $39.56 |
| Revenue Growth | ★ 48.29 | 7.45 |
| 52 Week Low | $6.25 | $108.75 |
| 52 Week High | $34.39 | $195.97 |
Technical Indicators
Market Signals| Indicator | TNGX | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.34 | 81.66 |
| Support Level | $19.74 | $163.18 |
| Resistance Level | $26.38 | $163.94 |
| Average True Range (ATR) | 1.40 | 0.33 |
| MACD | -0.20 | -1.48 |
| Stochastic Oscillator | 18.08 | 97.92 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.